Responses
Regular and Young Investigator Award Abstracts
Clinical Trial Completed
629 Neoadjuvant SEMA4D inhibitor pepinemab combination with nivolumab increases crosstalk between B cell and CD26hi T cell in patients with resectable stage III melanoma
Compose a Response to This Article
Other responses
No responses have been published for this article.
